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Background
The distinction between treatment effect and recurrent brain malignancy has been a controversial
topic for quite some time, with various proponents and opponents for the various cross-sectional
neuroimaging modalities. The goal of this manuscript is to provide the latest information on
positron emission tomography (PET) molecular imaging, offer other options within the realm of
molecular imaging, and to let the reader’s ultimate decision regarding follow-up imaging be made
on a case-by-case basis based upon available resources and user experience.
Delineation between treatment effect and tumor recurrence is an exceedingly important decision
in the era of more focused, targeted therapy, whether anti-angiogenic, immunologic, or radiother-
apy. The consequences of an incorrect assessment are obvious, leading to unnecessary treatment
and morbidity, delayed treatment, or shortened survival. Various modalities have been proposed to
follow such lesions after initial treatment: MRI, MRS, brain PET, and brain single photon emission
computed tomography (SPECT). Only molecular imaging (PET and SPECT) will be discussed in
this article.
Molecular imaging is distinguished from anatomical imaging in that it requires intact intra-
and extra-cellular architecture, whereas anatomical imaging only requires an intact structure.
Cancer begins at a cellular level, and thusly, microscopic changes precede macroscopic changes. No
imaging modality can replace a microscopic diagnosis, but current technology attempts to model a
microscopic process non-invasively. This has inherent implications of:
1. A radiographically negative scan cannot exclude microscopic disease.
2. Molecular imaging depends on specific substrate metabolism by tumors. If the particular
tumor cannot metabolize or concentrate the substrate, false negative scans will occur.
3. False positive scans can occur when substrates are metabolized or concentrated by cells related
to non-neoplastic processes, such as inflammation or infection.
These implications lead to the paradigmof follow up imaging after initial diagnosis and treatment:
how to separate cases of residual/recurrent disease from treatment response. The optimal imaging
algorithm has not been clearly delineated.
Molecular Imaging Modalities
Brain PET/CT
Positron emission tomography with or without inline computed tomography (CT) imaging has
largely overtaken clinical SPECT imaging of the brain for functional and oncological purposes.
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The increased resolution of PET (3mm theoretical) and shorter
acquisition times (10min) have significant advantages over
SPECT imaging. At our institution, brain PET has largely replaced
brain SPECT for both oncologic and neurologic indications. Pre-
viously, the number of PET cameras limited the availability to PET
imaging, but currently, most tertiary medical centers have access
to PET imaging (1). The number of installed PET/CT scanners
and procedures also appears to have plateaued, however.
Positron emitting isotopes are limited in the United States, as
only 18-F-fluoro-de-oxy-glucose (FDG), 11-C-choline, and 18-
F-sodium fluoride (NaF) are currently approved by the FDA for
routine clinical use. Sodium fluoride is a bone imaging agent, and
11-C-choline is only approved for prostate cancer imaging in the
United States. Promising agents include O-2-18-F-flourorethyl-
-tyrosine (FET), 18-F-fluoro-dopamine (F-DOPA), 18-F-flouro-
thymidine (FLT), and 11-C-methionine (MET); however, these
are only approved under an Investigational New Drug (IND)
application in theUnited States and are not commercially available
for routine clinical use outside of a research protocol. The main
topic of this article will be the use of 18-F-FDG-PET/CT.
Flouro-deoxy-glucose is structurally very similar to glucose,
with the number 2 hydroxyl group substituted with F-18. It
becomes a charged particle and is excretedmainly via the kidneys.
However, tumor cells are unable to distinguish FDG from glucose
and transport it through the cell membrane into the intracellular
space, where it is phosphorylated by hexokinase into FDG-6-
phosphate. Due to the polarity as well as faulty cellular enzyme
machinery, FDG-6-phosphate becomes trapped within cancer
cells and undergoes positron emission radioactive decay, thus
localizing its distribution within the body and organs, specifically
the brain in this discussion. Hence, cancer cells will concentrate
FDG, although to varying degrees, often related to the degree of
de-differentiation of the tumor. Increasing levels of FDG uptake
associated with higher grades of gliomas has been well docu-
mented (2–4). However, background uptake of FDG by normal
brain cells is quite high, leading to decreased target to background
ratios. This leads to lowered overall sensitivity for FDG-PET
imaging compared to a radiotracer, which is not normally metab-
olized by the brain, e.g., tyrosine, choline, thymidine, methionine,
or dopamine. As a result, there is significant promise in these
tracers, but they are not available for routine use in the US at this
time. In addition, despite the increased uptake of FDG (or any
other metabolic marker) within primary tumor cells, other types
of metabolically active cells may concentrate the tracer, namely
inflammatory cells such as neutrophils andmacrophages (5). This
confounds the interpretation of subsequent PET/CT studies both
during and after treatment for gliomas, since both medication
and radiation can induce inflammation to varying degrees and at
different times. Hence, follow-up FDG-PET/CT imaging is less
accurate than imaging at initial diagnosis for tumor detection.
However, PET imaging has a clear advantage in that individual
lesion tracer uptake can be quantified with the SUV, which is a
reproducible measurement of the degree of uptake within a given
lesion. A volumetric total lesion uptake can also be calculated in
cases of significant disease burden. There has been considerable
discussion and controversy as to the utility of FDG-PET/CT imag-
ing in the setting of routine follow-up during and after treatment
for malignant gliomas with conflicting data. The majority of
false positive studies relate to underlying inflammation, with the
majority of false negative studies due to small lesion size and low
lesion grade (4). Follow-up imaging time after therapy is also
controversial, with too early imaging potentially inaccurate due
to acute inflammation, and too late imaging potentially missing
opportunity for shifting the treatment scheme. Serial imaging is
also useful because of the reproducibility of PET results. The
trend of lesion uptake may be just as important as the absolute
uptake. Benign uptake would be expected to be stable, over time,
despite the absolute value. Malignant uptake would be expected to
increase with time. Given comparable sensitivity of PET imaging
(up to 77% using FDG-PET and 92% using 11-C-choline PET)
with contrast-enhanced MRI (up to 87%) (6–8), it is the author’s
opinion that while FDG-PET/CT imaging is the best choice at
this time, given its relatively widespread availability, the future of
neuroimaging is imaging with other tracers combined with MRI.
More and more studies are showing better agreement between
modalities when results are combined, rather than independently
analyzed (4). 11-C-choline, in particular, shows promise (9), but
is limited by its short half life of 20min. 18-F-FET imaging shows
greater promise, particularly with anti-angiogenic therapy (10–
12), but is not approved for clinical use in the United States.
Brain SPECT
Single photon emission computed tomography (SPECT) has been
utilized for several decades in nuclear medicine imaging. It allows
for tomographic rather than planar images and improves diag-
nostic accuracy. It, however, has limitations of spatial resolution
and long imaging times. Spatial resolution is approximately 1 cm
under ideal conditions and imaging times can be up to 45min
per acquisition. Both of these can limit its usefulness in the
setting of distinguishing between tumor recurrence and post-
treatment changes. However, for facilities without access to PET
imaging, brain SPECT can still provide useful information, as
SPECT gamma cameras are more widely accessible than PET
scanners. Currently, the only clinically available brain SPECT
agent for use in this setting in the US is Thallium-201 chloride.
Previous studies have suggested relative robust accuracy with Th-
201 (13); however, its popularity has shifted, due to increasing
availability of 18-F-FDG. However, the concepts are the same, if
the reader chooses to utilize Thallium brain SPECT imaging. In
our experience, brain SPECT imaging is inferior to brain PET/CT
imaging due to the slower throughput and inability to quantify
changes that occur with time or to quantify individual findings
seen on a single scan. The reader is left to subjectively describe
changes and relative uptake, which often makes interpretation
difficult. But SPECT imaging remains a viable option for facilities
without access to PET.
Conclusion
Molecular imaging in the setting of detecting recurrent disease
and delineating treatment effect is an evolving topic, with mul-
tiple promising, newer agents being evaluated, particularly, PET
tracers. The future of imaging in this setting is likely going to
be a combination of multiple modalities with possibly multiple
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radiotracers. Serial imaging is likely to be important as well. Fur-
ther research is underway to define the optimal imaging protocols.
Ultimately, at this time, determining the most accurate modality
is up to the reader, who must determine the best compromise,
given what resources are available and his or her comfort level in
interpreting the radiographic findings, but the author’s opinion is
that molecular imaging is the best single imaging modality at this
time, with combined multimodality imaging soon to become the
top choice, particularly when radiotracers only currently used for
research become available for widespread clinical use.
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